Chong Kun Dang Pharmaceutical (KRX: 185750)

Chong Kun Dang Pharmaceutical is a corporation based in Seoul, South Korea. Established in 1941, the firm is a manufacturer of antibiotics. It manufactures and distributes over 130 ethical, OTC pharmaceuticals and pharmaceutical active ingredients, primarily focusing on the application of its advanced technologies in fermentation and organic synthesis. The product range includes Rifampicin (antituberculosis), DMCT (raw material for Minocycline), Cephalosporins, 7-ACA, and other intermediates of Cephalosporins, Cyclosporin A (immunosuppressant) and Lovastatin (antihyperlipidaemic agent). The assets of the firm are managed by the executive management team.